Loading…

Human papillomavirus infection mediates response and outcome of vulvar squamous cell carcinomas treated with radiation therapy

Human papillomavirus (HPV) is implicated as a causative factor in vulvar squamous cell carcinoma (VSCC). This study evaluates if p16-positivity, a surrogate for HPV, predicts for better response rates to chemoradiation therapy and survival. We conducted a retrospective chart review of women treated...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2018-10, Vol.151 (1), p.96-101
Main Authors: Horne, Z.D., Dohopolski, M.J., Pradhan, D., Bhargava, R., Edwards, R.P., Kelley, J.L., Comerci, J.T., Olawaiye, A.B., Courtney-Brooks, M.B., Bockmeier, M.M., Berger, J.L., Taylor, S.E., Sukumvanich, P., Beriwal, S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human papillomavirus (HPV) is implicated as a causative factor in vulvar squamous cell carcinoma (VSCC). This study evaluates if p16-positivity, a surrogate for HPV, predicts for better response rates to chemoradiation therapy and survival. We conducted a retrospective chart review of women treated with neoadjuvant or definitive chemoradiation (CRT) therapy from 2000 to 2016 for VSCC. p16 stain-positivity was defined as diffuse strong “block” immunoreactivity within invasive tumor. Seventy-three women with median follow-up of 13.4 months were analyzed. Thirty-three (45.2%) had p16+ tumors. Median age was 73 years (range: 37–89); with p16+ tumors, the median age was 60 years vs 73 years for women with p16− tumors (p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2018.08.002